S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia|
|Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder|
|Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment|
|Alkermes shares up 5% on news of positive trial for schizophrenia drug|
|Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer|
|Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer|
|Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference|
|Alkermes plc Reports Third Quarter 2014 Financial Results|
|Alkermes’ Corporate Presentation to be Webcast at The NASDAQ OMX 31st Investor Program|
|Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference|
Click above to view more mutual fund data and stats for alk - Alkane Resources Ltd.